

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 November 2021 (11.11.2021)



(10) International Publication Number
WO 2021/226553 A3

(51) International Patent Classification:

C07K 14/705 (2006.01) C07K 14/71 (2006.01)
A61P 37/00 (2006.01) C07K 16/28 (2006.01)
C07K 19/00 (2006.01)

(21) International Application Number:

PCT/US2021/031432

(22) International Filing Date:

07 May 2021 (07.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/022,373	08 May 2020 (08.05.2020)	US
63/034,361	03 June 2020 (03.06.2020)	US
63/080,643	18 September 2020 (18.09.2020)	US

(71) Applicant: **ALPINE IMMUNE SCIENCES, INC.**
[US/US]; 188 East Blaine Street, Suite 200, Seattle, Wash-
ington 98102 (US).

(72) Inventors: **DILLON, Stacey**; 188 East Blaine Street, Suite
200, Seattle, Washington 98102 (US). **RIXON, Mark**; 188
East Blaine Street, Suite 200, Seattle, Washington 98102
(US). **EVANS, Lawrence**; 188 East Blaine Street, Suite
200, Seattle, Washington 98102 (US). **DEMONTE, Daniel
William**; 188 East Blaine Street, Suite 200, Seattle, Wash-
ington 98102 (US). **KULJPER, Joseph L.**; 188 East Blaine
Street, Suite 200, Seattle, Washington 98102 (US). **PENG,
Stanford L.**; 188 East Blaine Street, Suite 200, Seattle,
Washington 98102 (US). **SWANSON, Ryan**; 188 East
Blaine Street, Suite 200, Seattle, Washington 98102 (US).

(74) Agent: **POTTER, Karen** et al.; Morrison & Foerster LLP,
12531 High Bluff Drive, Suite 100, San Diego, California
92130-2040 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

28 April 2022 (28.04.2022)

(54) Title: APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS WITH AND WITHOUT A T CELL INHIBI-
TORY PROTEIN AND METHODS OF USE THEREOF

(57) Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/
APRIL heterotrimers) alone, or also coupled with inhibition of T cell costimulation. The immunomodulatory proteins provided herein
include variant domains of B cell maturation antigen (BCMA) alone, or multi-domain immunomodulatory protein that inhibit B cell
responses and also can inhibit T cell costimulation. Also provided are nucleic acids molecules encoding the immunomodulatory proteins.
The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases or conditions. Also provided are
compositions and methods for making and using such proteins.



WO 2021/226553 A3